Financial reports
Current reports
6-K
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
12 Apr 24
6-K
Report of Foreign Private Issuer
10 Apr 24
6-K
Report of Foreign Private Issuer
9 Apr 24
6-K
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
5 Apr 24
6-K
Report of Foreign Private Issuer
22 Feb 24
6-K
Report of Foreign Private Issuer
7 Feb 24
6-K
Report of Foreign Private Issuer
9 Jan 24
6-K
Report of Foreign Private Issuer
9 Jan 24
6-K
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
27 Dec 23
6-K
Report of Foreign Private Issuer
21 Dec 23
Registration and prospectus
D
$4.47 mm in options / securities to be acquired, sold $4.47 mm, 1 investor
25 Apr 24
424B5
Prospectus supplement for primary offering
12 Apr 24
POS AM
Prospectus update (post-effective amendment)
4 Apr 24
POS AM
Prospectus update (post-effective amendment)
4 Apr 24
424B3
Prospectus supplement
27 Dec 23
424B3
Prospectus supplement
14 Dec 23
424B3
Prospectus supplement
5 Dec 23
424B3
Prospectus supplement
5 Dec 23
POS AM
Prospectus update (post-effective amendment)
4 Dec 23
POS AM
Prospectus update (post-effective amendment)
21 Nov 23
Proxies
No filings
Other
EFFECT
Notice of effectiveness
9 Apr 24
EFFECT
Notice of effectiveness
9 Apr 24
EFFECT
Notice of effectiveness
5 Dec 23
CORRESP
Correspondence with SEC
4 Dec 23
EFFECT
Notice of effectiveness
6 Sep 23
CORRESP
Correspondence with SEC
31 Aug 23
CORRESP
Correspondence with SEC
14 Aug 23
UPLOAD
Letter from SEC
1 Aug 23
EFFECT
Notice of effectiveness
31 Jan 23
CORRESP
Correspondence with SEC
26 Jan 23
Ownership
SC 13G/A
Gordon Ariel
13 Feb 24
SC 13G/A
Ben-Noon Alon
13 Feb 24
SC 13G/A
Ben-Noon Alon
5 Apr 23
SC 13G/A
Gordon Ariel
15 Mar 23
SC 13G/A
E Europe Ltd
15 Mar 23
SC 13G
Real Property International Ltd
15 Mar 23
SC 13G
E Europe Ltd
30 Dec 21
SC 13G
Ben-Noon Alon
23 Dec 21
SC 13G
Gordon Ariel
20 Dec 21